Two new studies report the identification of activating ESR1 gene mutations in aromatase inhibitor–resistant metastatic breast cancers. This insight into therapeutic resistance suggests new approaches that may be useful in the management of endocrine-resistant breast cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
SABCS 2017 pathology: from bench to bedside
memo - Magazine of European Medical Oncology Open Access 15 August 2018
-
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models
Breast Cancer Research Open Access 23 May 2017
-
Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer
Oncogene Open Access 17 October 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Katie Vicari
References
Cancer Genome Atlas Network. Nature 490, 61–70 (2012).
Li, S. et al. Cell Rep. 4, 1116–1130 (2013).
Robinson, D.R. et al. Nat. Genet. 45, 1446–1451 (2013).
Toy, W. et al. Nat. Genet. 45, 1439–1445 (2013).
Baselga, J. et al. N. Engl. J. Med. 366, 520–529 (2012).
Ellis, M.J. et al. Nature 486, 353–360 (2012).
Carlson, K.E., Choi, I., Gee, A., Katzenellenbogen, B.S. & Katzenellenbogen, J.A. Biochemistry 36, 14897–14905 (1997).
Lazennec, G., Ediger, T.R., Petz, L.N., Nardulli, A.M. & Katzenellenbogen, B.S. Mol. Endocrinol. 11, 1375–1386 (1997).
Pakdel, F., Reese, J.C. & Katzenellenbogen, B.S. Mol. Endocrinol. 7, 1408–1417 (1993).
Weis, K.E., Ekena, K., Thomas, J.A., Lazennec, G. & Katzenellenbogen, B.S. Mol. Endocrinol. 10, 1388–1398 (1996).
Zhang, Q.X., Borg, A., Wolf, D.M., Oesterreich, S. & Fuqua, S.A. Cancer Res. 57, 1244–1249 (1997).
Le Goff, P., Montano, M.M., Schodin, D.J. & Katzenellenbogen, B.S. J. Biol. Chem. 269, 4458–4466 (1994).
Ali, S., Metzger, D., Bornert, J.M. & Chambon, P. EMBO J. 12, 1153–1160 (1993).
Lannigan, D.A. Steroids 68, 1–9 (2003).
Sherbenou, D.W. & Druker, B.J. J. Clin. Invest. 117, 2067–2074 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Oesterreich, S., Davidson, N. The search for ESR1 mutations in breast cancer. Nat Genet 45, 1415–1416 (2013). https://doi.org/10.1038/ng.2831
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.2831
This article is cited by
-
SABCS 2017 pathology: from bench to bedside
memo - Magazine of European Medical Oncology (2018)
-
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models
Breast Cancer Research (2017)
-
Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer
Oncogene (2017)
-
Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts
Hormones and Cancer (2017)
-
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Nature Communications (2016)
